Table 1.
Factors affecting engraftment rates in primary EOC-PDX models.
| Factors | N | Success | Failure | p-value | |
|---|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | ||||
| Age (years) | 137 | 56.68 ± 9.26 | 54.70 ± 10.52 | 0.245 | |
| CA125 (U/ml) | 137 | 400.6 | 316.75 | 0.854 | |
| (121.1, 1,012) | (65.88, 847.90) | ||||
| NACT | 0.018 | 0.045 | |||
| Yes | 62 | 28 | 34 | ||
| No | 75 | 49 | 26 | ||
| Surgical Satisfaction | 0.289 | 0.283 | |||
| R0 | 88 | 46 | 42 | ||
| R1 | 32 | 21 | 11 | ||
| Non-satisfaction | 1 | 1 | 0 | ||
| Pathological type | 0.259 | 0.772 | |||
| Type I EOC | 24 | 11 | 13 | ||
| Type II EOC | 113 | 66 | 47 | ||
| Cancer grade | 0.179 | 0.203 | |||
| Low–intermediate | 9 | 3 | 6 | ||
| High | 128 | 74 | 54 | ||
| FIGO stage | 0.589 | ||||
| II | 13 | 6 | 7 | ||
| III | 95 | 56 | 39 | ||
| IV | 29 | 15 | 14 | ||
| Ki-67(positive%) | 127 | 60% | 40% | <0.001 | 0.013 |
| (40%, 80%) | (21.25%, 60%) | ||||
| TP53 | 0.353 | ||||
| Wild type | 31 | 15 | 16 | ||
| Mutant type | 102 | 59 | 43 | ||
| BRCA1/2 | 0.445 | ||||
| Wild type | 52 | 31 | 21 | ||
| Mutant type | 22 | 11 | 11 | ||
| Response to Platinum | 0.978 | ||||
| Sensitive | 79 | 45 | 34 | ||
| Negative | 28 | 16 | 12 | ||
Age is described as mean ± SD, and CA125 and Ki-67 level are described as median (quartiles).
EOC, epithelial ovarian cancer; PDX, patient-derived xenograft; NACT, neoadjuvant chemotherapy; FIGO, International Federation of Gynecology and Obstetrics.